Related Experiment Videos
[Activation of the complement system in dilated cardiomyopathy]
Insights
Elevated anaphylatoxin C3a levels are linked to dilated cardiomyopathy (DCMP) and associated thromboembolic complications. This finding suggests a role for anaphylatoxins in DCMP pathogenesis.
Area of Science:
- Immunology
- Cardiology
- Biochemistry
Context:
- Cardiomyopathy, including dilated (DCMP) and hypertrophic (HCMP) forms, represents a significant clinical challenge.
- The complement system, particularly anaphylatoxins like C3a and C5a, plays a role in inflammatory and immune responses.
- Thromboembolic complications are a serious concern in patients with DCMP.
Purpose:
- To investigate the levels of anaphylatoxins (C3a, C5a) and other immune markers in patients with DCMP and HCMP.
- To explore the correlation between anaphylatoxin levels and the presence of thromboembolic complications in DCMP patients.
Summary:
- Blood levels of anaphylatoxins (C3a, C5a), complement components, antibodies, and immune complexes were measured in 21 DCMP/HCMP patients and 11 controls.
- Mean C3a levels were significantly higher in DCMP patients compared to HCMP patients and donors (p < 0.001).
- DCMP patients with thromboembolic complications showed significantly higher C3a concentrations than those without (p < 0.001). C5a levels did not differ significantly across groups.
Impact:
- These findings highlight the potential role of anaphylatoxins, specifically C3a, in the pathogenesis of DCMP.
- Elevated C3a may serve as a biomarker for increased risk of thromboembolic events in DCMP patients.
- Further research into the complement system's involvement could lead to novel therapeutic strategies for DCMP and its complications.
Abstract:
The levels of anaphylatoxins (C3a, C5a) in blood, components of complements C3 and C4, antibodies to cardiolipin, IgG, IgA, IgM, IgE and circulating immune complexes were measured in 21 patients with dilated and hypertrophic cardiomyopathy (DCMP and HCMP) and in 11 donors. The mean level of C3a in DCMP patients (572 +/- 55 ng/ml) was significantly higher than in HCMP patients (344 +/- 30 ng/ml) and in donors (294 +/- 43 ng/ml) (p less than 0.001). On comparison of C5a concentrations in DCMP patients (2.2 +/- 0.52 ng/ml), HCMP patients (3.3 +/- 1.2 ng/ml) and in donors (1.6 +/- 0.82 ng/ml) no significant differences were found (p greater than 0.05). It has been established that in the group of DCMP patients with thromboembolic complications, the concentrations of C3a (736 +/- 95 ng/ml) were significantly higher than in those without such complications (334 +/- 14 ng/ml) (p less than 0.001). The data obtained permit discussing the role of anaphylatoxins in the development of thromboembolic complications in DCMP patients.